VENTRINOVA

ventrinova-logo

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNovaโ€™s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.

#SimilarOrganizations #People #Financial #Website #More

VENTRINOVA

Industry:
Clinical Trials Genetics Therapeutics

Founded:
2006-01-01

Address:
New York, New York, United States

Country:
United States

Website Url:
http://www.ventrinovainc.com

Total Employee:
1+

Status:
Active

Contact:
508-362-3087

Total Funding:
1000 K USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API WordPress LetsEncrypt Font Awesome Mobile Non Scaleable Content IPv6 Cloudflare Hosting Wordpress Plugins


Similar Organizations

chaperone-therapeutics-logo

Chaperone Therapeutics

Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding

lannett-company-logo

Lannett Company

Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.

recensa-therapeutics-logo

Recensa Therapeutics

Recensa Therapeutics, Inc. has a new approach to treating psoriasis: targeting oxidative stress.


Current Advisors List

christopher-de-souza_image

Christopher de Souza Board Observer @ Ventrinova
Board_observer

Investors List

broadview-ventures_image

Broadview Ventures

Broadview Ventures investment in Seed Round - Ventrinova

Official Site Inspections

http://www.ventrinovainc.com

  • Host name: 104.21.50.97
  • IP address: 104.21.50.97
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Ventrinova"

Ventrinova - Crunchbase Company Profile & Funding

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells.See details»

VentriNova 2025 Company Profile: Valuation, Funding & Investors

Information on valuation, funding, cap tables, investors, and executives for VentriNova. Use the PitchBook Platform to explore the full profile.See details»

Centre de médecine régénérative

STRATÉGIE TRANSLATIONNELLE. L'administration par cathéter cardiaque dans le cล“ur infarci où les particules virales se diffusent rapidement dans le tissu myocardique et stimulent la division des cardiomyocytes sains matures dans โ€ฆSee details»

VentriNova Company Profile | Management and Employees List

Www.ventrinovainc.com . VentriNova Profile and History. VentriNova is a preclinical stage cardiac regenerative gene therapy company focused on reversing cardiac damage by activation of โ€ฆSee details»

VentriNova - VentureRadar

Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and โ€ฆSee details»

VentriNova Inc - Company Profile and News - Bloomberg Markets

Company profile page for VentriNova Inc including stock price, company news, executives, board members, and contact informationSee details»

VentriNova - Overview, News & Similar companies | ZoomInfo.com

View VentriNova (www.ventrinovainc.com) location in New York, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much โ€ฆSee details»

Ventrinova: Contact Details and Business Profile - RocketReach

VentriNova is a preclinical stage cardiac regenerative gene therapy company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart โ€ฆSee details»

VentriNova, Inc. | SBIR.gov

DESCRIPTION (provided by applicant): The morbidity and mortality due to cardiovascular disease is attributed to the lack of significant replicative potential of adult mammalian cardiomyocytes.See details»

VentriNova, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

Explore VentriNova, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»

VentriNova - Products, Competitors, Financials, Employees, โ€ฆ

VentriNova is a cardiac regenerative gene therapy company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. Use โ€ฆSee details»

VentriNova Inc | www.inknowvation.com

Business Identifier: Clinical treatments and gene therapy for the regeneration of heart tissueSee details»

Ventrinova - Tech Stack, Apps, Patents & Trademarks - Crunchbase

VentriNova is revolutionizing cardiac regenerative medicine by reversing cardiac damage pharmacologically.See details»

Ventrinova - Company Information, Competitors, News & FAQs

Find useful insights on Ventrinova's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at Ventrinova.See details»

VentriNova Company Profile | Industry Research and Analysis

Discover VentriNova, a trailblazer in advanced cardiovascular technologies. Specializing in innovative solutions for heart failure management, VentriNova provides cutting-edge devices โ€ฆSee details»

Ventrinova Culture | Comparably

Learn about Ventrinova's culture, see what work's like, read reviews, and find job opportunities.See details»

VentriNova | CipherBio

Explore VentriNova's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»

VentriNova's Gene Therapy Strategy Regenerates Heart Muscle โ€ฆ

Feb 20, 2014 About VN-100 VN-100, the company's lead product, is a viral vector-based gene therapy that induces cardiomyocyte division in adult heart tissue by delivery of cyclin A2, a โ€ฆSee details»

Research programme: CCNA2 gene therapy - VentriNova

25 Feb 2014 VentriNova is open to partnering opportunities for development of this research programme. www.ventrinovainc.com 19 Feb 2014 Preclinical trials in Myocardial infarction in โ€ฆSee details»

GE Vernovaโ€™s CEO on thriving through tariffs and supply chain โ€ฆ

2 hours ago GE Vernova is now one year into life as an independent public company, much to celebrateโ€”your revenue rose to $35 billion. In 2024, GE Vernova was the yearโ€™s fourth best โ€ฆSee details»

linkstock.net © 2022. All rights reserved